Keywords: Eisai, Halaven, Breast cancer, Shire, Vyvanse, ADHD, USA, FDA

US FDA approves Eisai’s Halaven for metastatic breast cancer and expanded use for Shire’s Vyvanse

Article | 16 November 2010

Print This

In a couple of positive opinions announced yesterday, the US Food and Drug Administration approved Japanese drug major Eisai’ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in